Freselestat (ONO-6818; 10-100 mg/kg; oral administration; daily; for 8 weeks) treatment attenuates dose-dependently HNE-induced increases in lung myeloperoxidase activity, hemoglobin, and neutrophil count in bronchoalveolar lavage fluid. ONO-6818 inhibits acute lung injury induced by HNE by minimizing lung hemorrhage and accumulation of neutrophils in the lung[1].
| Animal Model: | Male Wistar rats (228 g) induced by human neutrophil elastase (HNE)[1] |
| Dosage: | 10 mg/kg, 100 mg/kg |
| Administration: | Oral administration; daily; for 8 weeks |
| Result: | Attenuated dose-dependently HNE-induced increases in lung myeloperoxidase activity, hemoglobin, and neutrophil count in bronchoalveolar lavage fluid.
|
